— Know what they know.
Not Investment Advice

MDGL NASDAQ

Madrigal Pharmaceuticals, Inc.
1W: -4.9% 1M: -2.9% 3M: +18.1% YTD: -13.5% 1Y: +75.4% 3Y: +75.8% 5Y: +281.3%
$517.26
+3.67 (+0.71%)
 
Weekly Expected Move ±6.1%
$460 $492 $524 $555 $587
NASDAQ · Healthcare · Biotechnology · Alpha Radar Neutral · Power 50 · $11.9B mcap · 21M float · 1.57% daily turnover · Short 67% of daily vol

Cash Flow Trends

Operating Cash Flow
-$190M +58.4% ▲
Capital Expenditures
$467K +68.1% ▲
5Y CAGR: +6.9%
Free Cash Flow
-$190M +58.4% ▲
Dividends Paid
$0 +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
$99M +1835.0% ▲

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$242M-$295M-$374M-$466M-$288M
Depreciation & Amort.$405K$467K$527K$696K$5M
Stock-Based Comp.$27M$32M$50M$80M$98M
Change in Working Capital$31M$38M-$3M-$72M-$8M
Other Non-Cash Items$7M$797K$2M$2M$4M
Operating Cash Flow-$184M-$225M-$324M-$456M-$190M
— Investing Activities —
Capital Expenditures-$209K-$217K-$1M-$1M-$467K
Acquisitions (Net)$787K-$3K$0$0$0
Investment Purchases-$394M-$143M-$834M-$1.1B-$1.0B
Investment Sales$389M$350M$333M$839M$1.1B
Other Investing-$787K$3K$0$19M-$9M
Investing Cash Flow-$5M$207M-$503M-$274M$32M
— Financing Activities —
Net Debt Issuance$0$50M$65M$0$218M
Stock Repurchased$0$0$0$0$0
Dividends Paid$0$0$0$0$0
Other Financing$1M$8M$270M$338M$0
Financing Cash Flow$171M$313M$595M$735M$256M
Net Change in Cash-$18M$295M-$232M$5M$99M
Cash End of Period$36M$332M$100M$105M$204M
Free Cash Flow-$184M-$225M-$326M-$457M-$190M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms